Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 15/20 | 0.71 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | QPCTL | Q9NXS2 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267609 | 0.92 | QPCT (0.59) | QPCTMMP12QPCTL | |
| SCHEMBL2546387 | 0.91 | QPCT (0.83) | QPCTMMP12QPCTL | |
| SCHEMBL2546550 | 0.86 | QPCT (0.60) | QPCTMMP12QPCTL | |
| SCHEMBL2541701 | 0.83 | QPCT (1.00) | QPCTMMP12QPCTL | |
| SCHEMBL2546223 | 0.77 | QPCT (0.69) | QPCTMMP12QPCTL | |
| SCHEMBL15267629 | 0.74 | QPCT (0.84) | QPCTMMP12 | |
| SCHEMBL25425979 | 0.74 | QPCT (0.80) | QPCTMMP12QPCTL | |
| SCHEMBL30245579 | 0.74 | QPCT (0.80) | QPCTMMP12QPCTL | |
| SCHEMBL2540372 | 0.73 | QPCT (0.64) | QPCTMMP12QPCTL | |
| SCHEMBL12634028 | 0.73 | QPCT (0.47) | QPCTMMP12QPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | claimed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | claimed |
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | disclosed |
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885MMP12 3622/4885QPCTL 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.